Skip to main content
OpenTrials
Completed

NCT Number: NCT04357860

Clinical Trial of Sarilumab in Adults With COVID-19

Early administration of sarilumab in hospitalized patients infected with COVID-19 who have pulmonary infiltrates and are at high risk of unfavorable evolution could decrease/prevent progression to acute respiratory distress syndrome (ARDS) requiring high flow nasal oxygenation (HFNO) or either invasive or non-invasive mechanical ventilation.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Age range

18 year–75 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 2

Primary location

Hospital Universitario Reina Sofía

Córdoba, 14004, Spain

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Age ≥ 18 years and <75 years
  • Admission for confirmed respiratory symptoms to COVID-19 based on a positive PCR in a sample of the respiratory tract in the local laboratory in the absence of respiratory distress syndrome requiring ONAF or mechanical ventilation
  • Interstitial pneumonia confirmed by chest radiography or CT
  • IL-6 levels> 40 pg / ml. In its absence, D-Dimer (DD)> 1500 or> 1000 may be included if progressive increases are documented
  • Negative pregnancy test in women of childbearing age
  • Signature of informed consent

Exclusion criteria

  • SOFA score> 6 points
  • Patient who, in the researcher's opinion, is not a subsidiary of invasive mechanical ventilation
  • Neutrophil count <2 x 103 / μL
  • Platelet count <100 x 103 / μL
  • ALT or AST levels> 5 times the upper limit of normal
  • Severe renal failure (CrCr <30 ml / min)
  • Active bacterial infectious process
  • Active tuberculosis, history of not completing treatment against tuberculosis, suspicion of extrapulmonary tuberculosis
  • History of intestinal ulcer or diverticulitis
  • History of hypersensitivity reactions to Sarilumab or its excipients
  • Treatment with TNF antagonists
  • Previous treatment with anti-IL6 in the previous 30 days
  • Chronic prior treatment with corticosteroids at doses greater than 0.5 mg / kg / day of prednisone or equivalent. Yes, inhaled and topical corticosteroids are acceptable
  • Concomitant treatment with immunomodulators, among which are Vitamin D or statins. Macrolides such as azithromycin are acceptable
  • Patients on immunosuppressive treatment for any cause
  • HIV-infected patients with CD4 <200 / mm3
  • Past or current history of autoimmune disease or systemic inflammatory disease
  • Patients who have received or are planning therapy with immunomodulatory antibodies, including immunoglobulins
  • Participation in any clinical trial that evaluated any investigational product in the last 3 months or less than 5 half-lives of the investigational product
  • Pregnancy
  • Any other condition that, in clinical judgment, prevents adherence to the patient's protocol

Treatment and study plan

Sarilumab 200 MG/1.14 ML Subcutaneous Solution [KEVZARA]

Drug

Best available treatment up to 14 days plus Sarilumab 200 mg

Sarilumab 400 MG/2.28 ML Subcutaneous Solution [KEVZARA]

Drug

Best available treatment up to 14 days plus Sarilumab 400 mg

Best Available Treatment

Drug

Best available treatment up to 14 days

Primary outcomes

  1. Ventilation requirements

    Time frame: At day 28 or when the subject is discharged (whichever occurs first)

    Proportion of patients requiring or time (in days) until required:

    • High flow nasal oxygenation (HFNO)
    • Non-invasive mechanical ventilation type BiPAP
    • Non-invasive mechanical ventilation type CPAP
    • Invasive mechanical ventilation

Secondary outcomes

  1. Crude mortality

    Time frame: At day 28 or when the subject is discharged (whichever occurs first)

    Crude mortality at 28 days

  2. Time to clinical improvement

    Time frame: At day 28 or when the subject is discharged (whichever occurs first)

    Time to clinical improvement: defined as the mean change or time in days from randomization to any of the following criteria: (i) improvement of two points on the ordinal scale of 7 points of severity or, (ii) hospital discharge with lifetime. The criteria reached before are used. The 7 point gravity scale includes the following categories:

    • - Not hospitalized with normal activity
    • - Not hospitalized but unable to have normal activity
    • - Hospitalized, without requiring oxygen supplementation
    • - Hospitalized, requiring oxygen supplementation
    • - Hospitalized, requiring ONAF, non-invasive mechanical ventilation or both
    • - Hospitalized requiring ECMO, invasive mechanical ventilation or both
    • - Death
  3. Time until improvement in oxygenation

    Time frame: At day 28 or when the subject is discharged (whichever occurs first)

    Time (in days) until improvement in oxygenation for at least 48 hours:

    • Time to verify an increase in the SpO2 / FiO2 ratio with respect to the worst SpO2 / FiO2 prior to treatment with Sarilumab and stratified according to levels of IL-6 or DD
    • Time to absence of oxygen requirement to maintain saturation in ambient air ≥ 93%
    • Number of days in need of supplemental oxygen
  4. Proportion of patients requiring invasive mechanical ventilation

    Time frame: At day 28 or when the subject is discharged (whichever occurs first)

    Proportion of patients requiring invasive mechanical ventilation in the trial

  5. Proportion of patients having negative COVID-19 CRP at each visit

    Time frame: At day 28 or when the subject is discharged (whichever occurs first)

    Proportion of patients having negative COVID-19 CRP at each visit of the trial

  6. Mean of serum cytokine levels

    Time frame: At day 28 or when the subject is discharged (whichever occurs first)

    Mean of serum cytokine levels: the panel of cytokines to quantify; IL1-��, IL1-β, IL6, IL8, IL10, IL12, IL18, IL38, INFɣ, TNF��, CCL2, CCL3, CCL4, MIF and PAI-1

  7. Adverse events related to medication and its administration

    Time frame: At day 28 or when the subject is discharged (whichever occurs first)

    Incidence of adverse events related to medication and its administration

  8. Incidence in the appearance of serious bacterial, fungal or opportunistic infections

    Time frame: At day 28 or when the subject is discharged (whichever occurs first)

    Incidence in the appearance of serious bacterial, fungal or opportunistic infections in the subjects

  9. Incidence of perforation of the gastrointestinal tract

    Time frame: At day 28 or when the subject is discharged (whichever occurs first)

    Incidence of perforation of the gastrointestinal tract in subjects

  10. Leukocyte and neutrophil count

    Time frame: At day 28 or when the subject is discharged (whichever occurs first)

    Leukocyte and neutrophil count mean

  11. Hemoglobin levels

    Time frame: At day 28 or when the subject is discharged (whichever occurs first)

    Mean hemoglobin levels

  12. Platelet count

    Time frame: At day 28 or when the subject is discharged (whichever occurs first)

    Platelet count mean

  13. Levels of creatinemia

    Time frame: At day 28 or when the subject is discharged (whichever occurs first)

    Average levels of creatinemia

  14. Bilirubin levels

    Time frame: At day 28 or when the subject is discharged (whichever occurs first)

    Average bilirubin levels

  15. ALT and AST levels

    Time frame: At day 28 or when the subject is discharged (whichever occurs first)

    ALT and AST average levels

Sponsors and collaborators

Lead sponsor

Maimónides Biomedical Research Institute of Córdoba

Other

Collaborators

  • Junta de Andalucia
  • Red Andaluza de Ensayos Clínicos en Enfermedades Infecciosas (Red ANCRAID)

Registry information

Official study title

Clinical Trial of Sarilumab in Adults Hospitalized With COVID-19 Presenting Cytokine Release Syndrome

Acronym: SARICOR

Important dates

Study start
2020
Primary completion
2021
Study completion
2021
First posted
Apr 22, 2020
Registry last updated
Jul 7, 2021

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.